The discussion highlighted the successful phase I-B results for PH-762, with an 85% response rate and strong safety profile. INTASYL's unique delivery and gene-targeting capabilities position it as a versatile platform for oncology and beyond, with the next trial planned for early next year.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.